Schrödinger today announced that the Company will be presenting on its advanced computational platform, which integrates physics-based molecular simulation and machine learning to accelerate drug discovery, at the upcoming conferences in May:
About Schrödinger
Schrödinger has a substantial and growing
global business, licensing its industry-leading computational platform
to pharmaceutical, biotechnology, chemical, and electronics companies to
accelerate R&D in both drug discovery and materials design. Schrödinger
has built a robust pipeline of therapeutic assets, held both internally
and in partnerships, and has co-founded leading biotech companies,
including Nimbus Therapeutics and Morphic Therapeutic. Schrödinger’s
significant and ongoing investment in basic research continues to drive
advances in its computational platform. Founded in 1990, Schrödinger has
nearly 400 employees in its New York City headquarters and around the
world. Visit schrodinger.com
for more information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190513005169/en/
Media Contact:
Stephanie Simon
stephanie@tenbridgecommunications.com
617-581-9333
Investor
Contact:
Christina Tartaglia
Stern IR, Inc.
christina@sternir.com
212-362-1200